ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06351748. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
Open the trial in the graphWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReal-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR. This post hoc analysis investigated the use of combination semaglutide-sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment, glycated hemoglobin (HbA1c) changes, and safety in a subset of SCHOLAR participants.
methodsParticipants from SCHOLAR were included in this post hoc, single-arm analysis if they were prescribed once-weekly subcutaneous semaglutide and had ≥ 1 SGLT2i prescription within 6 months of initiating semaglutide. Participants were grouped according to whether semaglutide use was continuous or not and by baseline HbA1c (≥ 7%). We evaluated the proportion of SCHOLAR participants prescribed combined semaglutide-SGLT2i. Key endpoints were: change in HbA1c from baseline to month 6; proportion of participants achieving a HbA1c level < 7% at month 6; change in lipid profile from baseline to month 6; and safety profile of combined semaglutide-SGLT2i.
resultsA total of 11,361 (42.3%) SCHOLAR participants were treated with combined semaglutide-SGLT2i. Mean change in HbA1c (95% confidence interval [CI]) from baseline to month 6 was - 0.64%-points (- 0.71, - 0.56) (p < 0.0001) for the overall combined semaglutide-SGLT2i group. The greatest change was seen in the continuous semaglutide group with baseline HbA1c ≥ 7% (- 1.20%-points [95% CI - 1.36, - 1.04]). The proportion of participants with HbA1c levels < 7% increased from 37.8% at baseline to 55.1% at month 6 for the overall combined treatment group. There were significant reductions in mean total cholesterol (p < 0.0001), low-density lipoprotein cholesterol (p < 0.0001), and triglycerides (p = 0.0043) as well as a significant increase in high-density lipoprotein cholesterol (p < 0.0001). Gastrointestinal adverse events were most frequent.
conclusionsCombined semaglutide-SGLT2i treatment was prevalent in this subset of the SCHOLAR population and associated with significant reduction in HbA1c and changes in lipid profile. The safety profile of combined semaglutide-SGLT2i was similar to the overall SCHOLAR population. TRIAL REGISTRATION NUMBER: NCT06351748.
Indexed as
Identifiers
42803912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.